Indaptus Therapeutics, Inc. Liabilities Assumed
Indaptus Therapeutics, Inc. (INDP) reported Liabilities Assumed of $7.62 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-17.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2023-03-17
- Indaptus Therapeutics, Inc. liabilities assumed for the quarter ending 2021-12-31 was $0.00.
- Indaptus Therapeutics, Inc. liabilities assumed for fiscal 2021 was $7.62M.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $7.62M 10-K · filed 2023-03-17 | |
| 2021-09-30 | $7.62M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |